Immunogenetics of systemic sclerosis: Defining heritability, functional variants and shared-autoimmunity pathways

Journal of Autoimmunity

Volumn 64, Issue , 2015, Pages 53-65

  Bossini Castillo, Lara ^a   López Isac, Elena ^a   Martín, Javier ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Genetics; Heritability; Polymorphism; Shared loci; Systemic sclerosis

Indexed keywords

AUTOPHAGY PROTEIN 5; C SRC KINASE; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P35; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OX40 LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; PROTEIN BANK1; PROTEIN BLK; PROTEIN CD247; PROTEIN TNIP1; PROTEIN TYROSINE KINASE; STAT4 PROTEIN; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOPHAGY; FIBROSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEREDITY; HERITABILITY; HLA SYSTEM; HUMAN; IMMUNOGENETICS; INNATE IMMUNITY; META ANALYSIS (TOPIC); NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANIMAL; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; IMMUNOLOGY; METABOLISM; PHENOTYPE; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNITY; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; IMMUNOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK FACTORS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 84946478272     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.07.005     Document Type: Review

References (147)

1. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N. Engl. J. Med. 2009, 360(19):1989-2003.
2. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988 Feb, 15(2):202-205.
3. Amur S., Parekh A., Mummaneni P. Sex differences and genomics in autoimmune diseases. J. Autoimmun. 2012, 38(2-3):J254-J265.
4. M. Elhai, J. Avouac, U.A. Walker, M. Matucci-Cerinic, G. Riemekasten, P. Airo, et al., A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study, Ann. Rheum. Dis. Published Online First: October 31, 2014, . http://dx.doi.org/10.1136/annrheumdis-2014-206386.
5. Ranque B., Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun. Rev. 2010, 9(5):A311-A318.
6. Mayes M.D., Lacey J.V., Beebe-Dimmer J., Gillespie B.W., Cooper B., Laing T.J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003, 48(8):2246-2255.
7. Reveille J.D. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr. Rheumatol. Rep. 2003, 5(2):160-167.
8. Barnes J., Mayes M.D. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr. Opin. Rheumatol. 2012, 24(2):165-170.
9. Chifflot H., Fautrel B., Sordet C., Chatelus E., Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin. Arthritis Rheum. 2008, 37(4):223-235.
10. Arnett F.C., Howard R.F., Tan F., Moulds J.M., Bias W.B., Durban E., et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum. 1996, 39(8):1362-1370.
11. Reveille J.D., Fischbach M., McNearney T., Friedman A.W., Aguilar M.B., Lisse J., et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin. Arthritis Rheum. 2001, 30(5):332-346.
12. Mora G.F. Systemic sclerosis: environmental factors. J. Rheumatol. 2009, 36(11):2383-2396.
13. Hindorff L.A., Sethupathy P., Junkins H.A., Ramos E.M., Mehta J.P., Collins F.S., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(23):9362-9367.
14. Welter D., MacArthur J., Morales J., Burdett T., Hall P., Junkins H., et al. The NHGRI GWAS catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014, 42(Database issue):D1001-D1006.
15. Zhou X., Lee J.E., Arnett F.C., Xiong M., Park M.Y., Yoo Y.K., et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum. 2009, 60(12):3807-3814.
16. Radstake T.R., Gorlova O., Rueda B., Martin J.E., Alizadeh B.Z., Palomino-Morales R., et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat. Genet. 2010, 42(5):426-429.
17. Allanore Y., Saad M., Dieude P., Avouac J., Distler J.H., Amouyel P., et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet. 2011, 7(7):e1002091.
18. Mayes M.D., Bossini-Castillo L., Gorlova O., Martin J.E., Zhou X., Chen W.V., et al. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am. J. Hum. Genet. 2014, 94(1):47-61.
19. Parkes M., Cortes A., van Heel D.A., Brown M.A. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat. Rev. Genet. 2013, 14(9):661-673.
20. Arnett F.C., Gourh P., Shete S., Ahn C.W., Honey R.E., Agarwal S.K., et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann. Rheum. Dis. 2010, 69(5):822-827.
21. Gilchrist F.C., Bunn C., Foley P.J., Lympany P.A., Black C.M., Welsh K.I., et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun. 2001, 2(2):76-81.
22. Beretta L., Rueda B., Marchini M., Santaniello A., Simeon C.P., Fonollosa V., et al. Analysis of Class II human leucocyte antigens in Italian and Spanish systemic sclerosis. Rheumatol. Oxf. 2012, 51(1):52-59.
23. Vigone B., Santaniello A., Marchini M., Montanelli G., Caronni M., Severino A., et al. Role of class II human leucocyte antigens in the progression from early to definite systemic sclerosis. Rheumatol. Oxf. 2015, 54(4):707-711.
24. Raychaudhuri S., Sandor C., Stahl E.A., Freudenberg J., Lee H.S., Jia X., et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 2012, 44(3):291-296.
25. Jia X., Han B., Onengut-Gumuscu S., Chen W.M., Concannon P.J., Rich S.S., et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 2013, 8(6):e64683.
26. Eyre S., Bowes J., Diogo D., Lee A., Barton A., Martin P., et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat. Genet. 2012, 44(12):1336-1340.
27. Ombrello M.J., Kirino Y., de Bakker P.I., Gul A., Kastner D.L., Remmers E.F. Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(24):8867-8872.
28. Carmona F.D., Mackie S.L., Martin J.E., Taylor J.C., Vaglio A., Eyre S., et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am. J. Hum. Genet. 2015, 96(4):565-580.
29. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014, 14(1):36-49.
30. Wu M., Assassi S. The role of type 1 interferon in systemic sclerosis. Front. Immunol. 2013, 4:266.
31. Ito I., Kawaguchi Y., Kawasaki A., Hasegawa M., Ohashi J., Hikami K., et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum. 2009, 60(6):1845-1850.
32. Dieude P., Guedj M., Wipff J., Avouac J., Fajardy I., Diot E., et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum. 2009, 60(1):225-233.
33. Dieude P., Dawidowicz K., Guedj M., Legrain Y., Wipff J., Hachulla E., et al. Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. J. Rheumatol. 2010, 37(5):987-992.
34. Carmona F.D., Martin J.E., Beretta L., Simeon C.P., Carreira P.E., Callejas J.L., et al. The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. PLoS One 2013, 8(1):e54419.
35. Kottyan L.C., Zoller E.E., Bene J., Lu X., Kelly J.A., Rupert A.M., et al. The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Hum. Mol. Genet. 2015, 24(2):582-596.
36. Sharif R., Mayes M.D., Tan F.K., Gorlova O.Y., Hummers L.K., Shah A.A., et al. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann. Rheum. Dis. 2012, 71(7):1197-1202.
37. Zhao J., Kong H.J., Li H., Huang B., Yang M., Zhu C., et al. IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. J. Biol. Chem. 2006, 281(15):10073-10080.
38. Wang H., Lee C.H., Qi C., Tailor P., Feng J., Abbasi S., et al. IRF8 regulates B-cell lineage specification, commitment, and differentiation. Blood 2008, 112(10):4028-4038.
39. Gorlova O., Martin J.E., Rueda B., Koeleman B.P., Ying J., Teruel M., et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet. 2011, 7(7):e1002178.
40. Arismendi M., Giraud M., Ruzehaji N., Dieude P., Koumakis E., Ruiz B., et al. Identification of NF-kappaB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. Arthritis Res. Ther. 2015, 17(1):71.
41. Carmona F.D., Gutala R., Simeon C.P., Carreira P., Ortego-Centeno N., Vicente-Rabaneda E., et al. Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann. Rheum. Dis. 2012, 71(1):114-119.
42. Salloum R., Franek B.S., Kariuki S.N., Rhee L., Mikolaitis R.A., Jolly M., et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010, 62(2):553-561.
43. Chung S.A., Taylor K.E., Graham R.R., Nititham J., Lee A.T., Ortmann W.A., et al. Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet. 2011, 7(3):e1001323.
44. Catrysse L., Vereecke L., Beyaert R., van Loo G. A20 in inflammation and autoimmunity. Trends Immunol. 2014, 35(1):22-31.
45. Dieude P., Guedj M., Wipff J., Ruiz B., Riemekasten G., Matucci-Cerinic M., et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann. Rheum. Dis. 2010, 69(11):1958-1964.
46. Martin J.E., Broen J.C., Carmona F.D., Teruel M., Simeon C.P., Vonk M.C., et al. Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Hum. Mol. Genet. 2012, 21(12):2825-2835.
47. Koumakis E., Giraud M., Dieude P., Cohignac V., Cuomo G., Airo P., et al. Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis Rheum. 2012, 64(8):2746-2752.
48. Musone S.L., Taylor K.E., Lu T.T., Nititham J., Ferreira R.C., Ortmann W., et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat. Genet. 2008, 40(9):1062-1064.
49. Bossini-Castillo L., Martin J.E., Broen J., Simeon C.P., Beretta L., Gorlova O.Y., et al. Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study. Ann. Rheum. Dis. 2013, 72(4):602-607.
50. Katsumoto T.R., Whitfield M.L., Connolly M.K. The pathogenesis of systemic sclerosis. Annu. Rev. Pathol. 2011, 6:509-537.
51. Abraham D.J., Krieg T., Distler J., Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatol. Oxf. 2009, 48(Suppl. 3):iii3-7.
52. Gu Y.S., Kong J., Cheema G.S., Keen C.L., Wick G., Gershwin M.E. The immunobiology of systemic sclerosis. Semin. Arthritis Rheum. 2008, 38(2):132-160.
53. Matucci-Cerinic M., Kahaleh B., Wigley F.M. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013, 65(8):1953-1962.
54. Gough M.J., Weinberg A.D. OX40 (CD134) and OX40L. Adv. Exp. Med. Biol. 2009, 647:94-107.
55. Gourh P., Arnett F.C., Tan F.K., Assassi S., Divecha D., Paz G., et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann. Rheum. Dis. 2010, 69(3):550-555.
56. Bossini-Castillo L., Broen J.C., Simeon C.P., Beretta L., Vonk M.C., Ortego-Centeno N., et al. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann. Rheum. Dis. 2011, 70(4):638-641.
57. Coustet B., Bouaziz M., Dieude P., Guedj M., Bossini-Castillo L., Agarwal S., et al. Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosis. J. Rheumatol. 2012, 39(5):997-1003.
58. Komura K., Yoshizaki A., Kodera M., Iwata Y., Ogawa F., Shimizu K., et al. Increased serum soluble OX40 in patients with systemic sclerosis. J. Rheumatol. 2008, 35(12):2359-2362.
59. Dieude P., Boileau C., Guedj M., Avouac J., Ruiz B., Hachulla E., et al. Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor. Ann. Rheum. Dis. 2011, 70(9):1695-1696.
60. Levinson N.M., Seeliger M.A., Cole P.A., Kuriyan J. Structural basis for the recognition of c-Src by its inactivator Csk. Cell. 2008, 134(1):124-134.
61. Skhirtladze C., Distler O., Dees C., Akhmetshina A., Busch N., Venalis P., et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 2008, 58(5):1475-1484.
62. Fiorillo E., Orru V., Stanford S.M., Liu Y., Salek M., Rapini N., et al. Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue. J. Biol. Chem. 2010, 285(34):26506-26518.
63. Zhong M.C., Veillette A. Immunology: Csk keeps LYP on a leash. Nat. Chem. Biol. 2012, 8(5):412-413.
64. Diaz-Gallo L.M., Gourh P., Broen J., Simeon C., Fonollosa V., Ortego-Centeno N., et al. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann. Rheum. Dis. 2011, 70(3):454-462.
65. Dieude P., Guedj M., Wipff J., Avouac J., Hachulla E., Diot E., et al. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. Arthritis Rheum. 2008, 58(7):2183-2188.
66. Gourh P., Tan F.K., Assassi S., Ahn C.W., McNearney T.A., Fischbach M., et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum. 2006, 54(12):3945-3953.
67. Lee Y.H., Choi S.J., Ji J.D., Song G.G. The association between the PTPN22 C1858T polymorphism and systemic sclerosis: a meta-analysis. Mol. Biol. Rep. 2012, 39(3):3103-3108.
68. Liang Y., Pan H.F., Ye D.Q. Therapeutic potential of STAT4 in autoimmunity. Expert Opin. Ther. Targets 2014, 18(8):945-960.
69. Nguyen K.B., Watford W.T., Salomon R., Hofmann S.R., Pien G.C., Morinobu A., et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002, 297(5589):2063-2066.
70. Dieude P., Guedj M., Wipff J., Ruiz B., Hachulla E., Diot E., et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 2009, 60(8):2472-2479.
71. Gourh P., Agarwal S.K., Divecha D., Assassi S., Paz G., Arora-Singh R.K., et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum. 2009, 60(12):3794-3806.
72. Rueda B., Broen J., Simeon C., Hesselstrand R., Diaz B., Suarez H., et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum. Mol. Genet. 2009, 18(11):2071-2077.
73. Tsuchiya N., Kawasaki A., Hasegawa M., Fujimoto M., Takehara K., Kawaguchi Y., et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann. Rheum. Dis. 2009, 68(8):1375-1376.
74. Yi L., Wang J.C., Guo X.J., Gu Y.H., Tu W.Z., Guo G., et al. STAT4 is a genetic risk factor for systemic sclerosis in a Chinese population. Int. J. Immunopathol. Pharmacol. 2013, 26(2):473-478.
75. Avouac J., Furnrohr B.G., Tomcik M., Palumbo K., Zerr P., Horn A., et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum. 2011, 63(3):800-809.
76. Vignali D.A., Kuchroo V.K. IL-12 family cytokines: immunological playmakers. Nat. Immunol. 2012, 13(8):722-728.
77. Sato S., Hanakawa H., Hasegawa M., Nagaoka T., Hamaguchi Y., Nishijima C., et al. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J. Rheumatol. 2000, 27(12):2838-2842.
78. Bossini-Castillo L., Martin J.E., Broen J., Gorlova O., Simeon C.P., Beretta L., et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum. Mol. Genet. 2012, 21(4):926-933.
79. Lopez-Isac E., Bossini-Castillo L., Guerra S.G., Denton C., Fonseca C., Assassi S., et al. Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus. Arthritis Rheumatol. 2014, 66(12):3521-3523.
80. Westra H.J., Peters M.J., Esko T., Yaghootkar H., Schurmann C., Kettunen J., et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 2013, 45(10):1238-1243.
81. Takahashi N., Akahoshi M., Matsuda A., Ebe K., Inomata N., Obara K., et al. Association of the IL12RB1 promoter polymorphisms with increased risk of atopic dermatitis and other allergic phenotypes. Hum. Mol. Genet. 2005, 14(21):3149-3159.
82. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371(9625):1665-1674.
83. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371(9625):1675-1684.
84. Griffiths C.E., Strober B.E., van de Kerkhof P., Ho V., Fidelus-Gort R., Yeilding N., et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 2010, 362(2):118-128.
85. Dieude P., Wipff J., Guedj M., Ruiz B., Melchers I., Hachulla E., et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum. 2009, 60(11):3447-3454.
86. Rueda B., Gourh P., Broen J., Agarwal S.K., Simeon C., Ortego-Centeno N., et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann. Rheum. Dis. 2010, 69(4):700-705.
87. Gourh P., Agarwal S.K., Martin E., Divecha D., Rueda B., Bunting H., et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J. Autoimmun. 2010, 34(2):155-162.
88. Ito I., Kawaguchi Y., Kawasaki A., Hasegawa M., Ohashi J., Kawamoto M., et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum. 2010, 62(3):890-895.
89. Coustet B., Dieude P., Guedj M., Bouaziz M., Avouac J., Ruiz B., et al. C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysis. Arthritis Rheum. 2011, 63(7):2091-2096.
90. Shiokawa D., Tanuma S. Characterization of human DNase I family endonucleases and activation of DNase gamma during apoptosis. Biochemistry 2001, 40(1):143-152.
91. Errami Y., Naura A.S., Kim H., Ju J., Suzuki Y., El-Bahrawy A.H., et al. Apoptotic DNA fragmentation may be a cooperative activity between caspase-activated deoxyribonuclease and the poly(ADP-ribose) polymerase-regulated DNAS1L3, an endoplasmic reticulum-localized endonuclease that translocates to the nucleus during apoptosis. J. Biol. Chem. 2013, 288(5):3460-3468.
92. Okamoto M., Okamoto N., Yashiro H., Shiokawa D., Sunaga S., Yoshimori A., et al. Involvement of DNase gamma in the resected double-strand DNA breaks in immunoglobulin genes. Biochem. Biophys. Res. Commun. 2005, 327(1):76-83.
93. Zochling J., Newell F., Charlesworth J.C., Leo P., Stankovich J., Cortes A., et al. An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3. Arthritis Res. Ther. 2014, 16(5):438.
94. Al-Mayouf S.M., Sunker A., Abdwani R., Abrawi S.A., Almurshedi F., Alhashmi N., et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat. Genet. 2011, 43(12):1186-1188.
95. Choi A.M., Ryter S.W., Levine B. Autophagy in human health and disease. N. Engl. J. Med. 2013, 368(19):1845-1846.
96. Bhattacharya A., Eissa N.T. Autophagy and autoimmunity crosstalks. Front. Immunol. 2013, 4:88.
97. Lopez-Isac E., Bossini-Castillo L., Simeon C.P., Egurbide M.V., Alegre-Sancho J.J., Callejas J.L., et al. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Res. Ther. 2014, 16(1):R6.
98. Marangoni R.G., Korman B.D., Allanore Y., Dieude P., Armstrong L.L., Rzhetskaya M., et al. A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-gamma) gene and systemic sclerosis. Arthritis Res. Ther. 2015, 17:128.
99. Burgess H.A., Daugherty L.E., Thatcher T.H., Lakatos H.F., Ray D.M., Redonnet M., et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 2005, 288(6):L1146-L1153.
100. Kulkarni A.A., Thatcher T.H., Olsen K.C., Maggirwar S.B., Phipps R.P., Sime P.J. PPAR-gamma ligands repress TGFbeta-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One 2011, 6(1):e15909.
101. Wei J., Zhu H., Komura K., Lord G., Tomcik M., Wang W., et al. A synthetic PPAR-gamma agonist triterpenoid ameliorates experimental fibrosis: PPAR-gamma-independent suppression of fibrotic responses. Ann. Rheum. Dis. 2014, 73(2):446-454.
102. Wu M., Melichian D.S., Chang E., Warner-Blankenship M., Ghosh A.K., Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am. J. Pathol. 2009, 174(2):519-533.
103. Wei J., Ghosh A.K., Sargent J.L., Komura K., Wu M., Huang Q.Q., et al. PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010, 5(11):e13778.
104. Tenesa A., Haley C.S. The heritability of human disease: estimation, uses and abuses. Nat. Rev. Genet. 2013, 14(2):139-149.
105. Arora-Singh R.K., Assassi S., del Junco D.J., Arnett F.C., Perry M., Irfan U., et al. Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. J. Autoimmun. 2010, 35(1):52-57.
106. Feghali-Bostwick C., Medsger T.A., Wright T.M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003, 48(7):1956-1963.
107. Hill W.G., Mackay T.F., S D. Falconer and Introduction to quantitative genetics. Genetics 2004, 167(4):1529-1536.
108. Lee S.H., Wray N.R., Goddard M.E., Visscher P.M. Estimating missing heritability for disease from genome-wide association studies. Am. J. Hum. Genet. 2011, 88(3):294-305.
109. Yang J., Benyamin B., McEvoy B.P., Gordon S., Henders A.K., Nyholt D.R., et al. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 2010, 42(7):565-569.
110. Yang J., Lee S.H., Goddard M.E., Visscher P.M. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 2011, 88(1):76-82.
111. Visscher P.M., Hemani G., Vinkhuyzen A.A., Chen G.B., Lee S.H., Wray N.R., et al. Statistical power to detect genetic (co)variance of complex traits using SNP data in unrelated samples. PLoS Genet. 2014, 10(4):e1004269.
112. Chen G.B., Lee S.H., Brion M.J., Montgomery G.W., Wray N.R., Radford-Smith G.L., et al. Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data. Hum. Mol. Genet. 2014, 23(17):4710-4720.
113. Gusev A., Bhatia G., Zaitlen N., Vilhjalmsson B.J., Diogo D., Stahl E.A., et al. Quantifying missing heritability at known GWAS loci. PLoS Genet. 2013, 9(12):e1003993.
114. Wang K., Li M., Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010, 38(16):e164.
115. Okada Y., Wu D., Trynka G., Raj T., Terao C., Ikari K., et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014, 506(7488):376-381.
116. Bottini N., Peterson E.J. Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease. Annu. Rev. Immunol. 2014, 32:83-119.
117. Gupta B., Hawkins R.D. Epigenomics of autoimmune diseases. Immunol. Cell Biol. 2015, 93(3):271-276.
118. Lappalainen T., Sammeth M., Friedlander M.R., t Hoen P.A., Monlong J., Rivas M.A., et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 2013, 501(7468):506-511.
119. Kraja A.T., Vaidya D., Pankow J.S., Goodarzi M.O., Assimes T.L., Kullo I.J., et al. A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes 2011, 60(4):1329-1339.
120. Abbondanza C., De Rosa C., D'Arcangelo A., Pacifico M., Spizuoco C., Piluso G., et al. Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines. J. Cell Physiol. 2012, 227(3):964-975.
121. Tan L.Z., Song Y., Nelson J., Yu Y.P., Luo J.H. Integrin alpha7 binds tissue inhibitor of metalloproteinase 3 to suppress growth of prostate cancer cells. Am. J. Pathol. 2013, 183(3):831-840.
122. Elhai M., Avouac J., Kahan A., Allanore Y. Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun. Rev. 2013, 12(11):1052-1057.
123. Cotsapas C., Hafler D.A. Immune-mediated disease genetics: the shared basis of pathogenesis. Trends Immunol. 2013, 34(1):22-26.
124. Cortes A., Brown M.A. Promise and pitfalls of the Immunochip. Arthritis Res. Ther. 2011, 13(1):101.
125. Kim K., Bang S.Y., Lee H.S., Cho S.K., Choi C.B., Sung Y.K., et al. High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. Ann. Rheum. Dis. 2015, 74(3):e13.
126. Cooper J.D., Simmonds M.J., Walker N.M., Burren O., Brand O.J., Guo H., et al. Seven newly identified loci for autoimmune thyroid disease. Hum. Mol. Genet. 2012, 21(23):5202-5208.
127. Tsoi L.C., Spain S.L., Knight J., Ellinghaus E., Stuart P.E., Capon F., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 2012, 44(12):1341-1348.
128. Liu J.Z., Almarri M.A., Gaffney D.J., Mells G.F., Jostins L., Cordell H.J., et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat. Genet. 2012, 44(10):1137-1141.
129. Juran B.D., Hirschfield G.M., Invernizzi P., Atkinson E.J., Li Y., Xie G., et al. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum. Mol. Genet. 2012, 21(23):5209-5221.
130. Hinks A., Cobb J., Marion M.C., Prahalad S., Sudman M., Bowes J., et al. Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat. Genet. 2013, 45(6):664-669.
131. Liu J.Z., Hov J.R., Folseraas T., Ellinghaus E., Rushbrook S.M., Doncheva N.T., et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat. Genet. 2013, 45(6):670-675.
132. Faraco J., Lin L., Kornum B.R., Kenny E.E., Trynka G., Einen M., et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet. 2013, 9(2):e1003270.
133. Ellinghaus D., Baurecht H., Esparza-Gordillo J., Rodriguez E., Matanovic A., Marenholz I., et al. High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. Nat. Genet. 2013, 45(7):808-812.
134. Cortes A., Hadler J., Pointon J.P., Robinson P.C., Karaderi T., Leo P., et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat. Genet. 2013, 45(7):730-738.
135. Saruhan-Direskeneli G., Hughes T., Aksu K., Keser G., Coit P., Aydin S.Z., et al. Identification of multiple genetic susceptibility loci in Takayasu arteritis. Am. J. Hum. Genet. 2013, 93(2):298-305.
136. Martin J.E., Assassi S., Diaz-Gallo L.M., Broen J.C., Simeon C.P., Castellvi I., et al. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum. Mol. Genet. 2013, 22(19):4021-4029.
137. Zhernakova A., Stahl E.A., Trynka G., Raychaudhuri S., Festen E.A., Franke L., et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet. 2011, 7(2):e1002004.
138. Ellinghaus D., Ellinghaus E., Nair R.P., Stuart P.E., Esko T., Metspalu A., et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am. J. Hum. Genet. 2012, 90(4):636-647.
139. Festen E.A., Goyette P., Green T., Boucher G., Beauchamp C., Trynka G., et al. A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet. 2011, 7(1):e1001283.
140. Delgado-Vega A., Sanchez E., Lofgren S., Castillejo-Lopez C., Alarcon-Riquelme M.E. Recent findings on genetics of systemic autoimmune diseases. Curr. Opin. Immunol. 2010, 22(6):698-705.
141. Teruel M., McKinney C., Balsa A., Pascual-Salcedo D., Rodriguez-Rodriguez L., Ortiz A.M., et al. Association of CD247 polymorphisms with rheumatoid arthritis: a replication study and a meta-analysis. PLoS One 2013, 8(7):e68295.
142. Barnes J., Agarwal S.K. Targeting STAT4 in systemic sclerosis: a promising new direction. Expert Rev. Clin. Immunol. 2011, 7(4):445-448.
143. Hudson M., Rojas-Villarraga A., Coral-Alvarado P., Lopez-Guzman S., Mantilla R.D., Chalem P., et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J. Autoimmun. 2008, 31(2):156-159.
144. Glas J., Seiderer J., Markus C., Pfennig S., Wetzke M., Paschos E., et al. Role of PPARG gene variants in inflammatory bowel disease. Inflamm. Bowel Dis. 2011, 17(4):1057-1058.
145. Zhang Z.F., Yang N., Zhao G., Zhu L., Wang L.X. Association between the Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and inflammatory bowel disease: a meta-analysis. PLoS One 2012, 7(1):e30551.
146. Butt C., Gladman D., Rahman P. PPAR-gamma gene polymorphisms and psoriatic arthritis. J. Rheumatol. 2006, 33(8):1631-1633.
147. Lyssenko V., Jonsson A., Almgren P., Pulizzi N., Isomaa B., Tuomi T., et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N. Engl. J. Med. 2008, 359(21):2220-2232.